Journal issues > Issue Special, February 2023 > Ethics & Economy – How to get a drug reimbursed in Belgium?

Ethics & Economy – How to get a drug reimbursed in Belgium?

By: J. Blokken PhD, PharmD, T. Feys MBA, MSc

The journey a drug makes from the laboratory to the patient’s bedside is very long. After years of clinical research and development, a lengthy administrative procedure needs to be completed. It starts with the granting of a marketing authorisation by the EMA and is followed in Belgium by a reimbursement decision. In order to get a better view on how a drug gets reimbursed in Belgium, Diane Kleinermans (RIZIV-INAMI, President CRM/CTG, Brussels), Marjan Willaert (Policy Advisor – Market Access, Pharma.be, Brussels), and Hanne Wouters (Market Access Advisor, Pharma.be, Brussels) gave an overview on the evaluation and review by the commission for reimbursement of medicines (CRM).

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top